한빛사논문
- 조회606
Min Joo Choi 1†, Yewon Na 2,3†, Hak Jun Hyun 4, Eliel Nham 5, Jin Gu Yoon 5, Hye Seong 5, Yu Bin Seo 6, Won Suk Choi 5, Joon Young Song 5, Dong Wook Kim 7,8, Young-Eun Kim 9, Jaehun Jung 10, Hee Jin Cheong 5
1Department of Internal Medicine, Catholic Kwandong University College of Medicine, International St. Mary's Hospital, Incheon, Korea
2Graduate School of Public Health, Seoul National University, Seoul, Korea
3Artificial Intelligence and Big-data Convergence Center, Gachon University Gil Medical Center, Incheon, Korea
4Department of Internal Medicine, Ajou University Hospital, Suwon, Korea
5Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea
6Department of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea
7Department of Information and Statistics, Research Institute of Natural Science, Gyeongsang National University, Jinju, Korea
8Department of Bio & Medical Bigdata Department, Research Institute of Natural Science, Gyeongsang National University, Jinju, Korea
9Department of Big Data Strategy, National Health Insurance Service, Wonju, Korea
10Department of Preventive Medicine, Gachon University College of Medicine, Incheon, Korea
†These authors contributed equally to this paper.
Corresponding authors: Jaehun Jung, Hee Jin Cheong
Abstract
Objective: This nationwide cohort study compared the incidence of adverse events of special interest (AESIs) between adenoviral vector- (ChAdOx1) and mRNA-based (BNT162b2 or mRNA-1273) coronavirus disease 2019 (COVID-19) vaccines.
Methods: A targeted trial emulation study was conducted using data from the National Health Insurance Service database. Vaccinees aged 18-85 years who had received at least one dose of ChAdOx1 or an mRNA-based vaccine were identified. The 42-day risks of AESIs were calculated.
Results: A total of 1,767,539 ChAdOx1 vaccinees were matched exactly with mRNA vaccinees according to their risk factors. The 42-day risks of adverse events were low (approximately 0 to 176 events per 100,000 persons in both vaccine groups), and the incidence rates of AESIs were comparable between the two platforms, except for a higher occurrence of acute cardiac injury (incidence rate ratio [IRR] = 1.22, 95% confidence interval [CI] 1.10-1.35), myocarditis/pericarditis (IRR = 2.14, 95% CI 1.14-4.04), and arrhythmia (IRR = 1.46, 95% CI 1.24-1.71) in mRNA vaccinees. The incidence of Guillain-Barré syndrome (IRR = 0.20, 95% CI 0.06-0.69), vasovagal syncope (IRR = 0.77, 95% CI 0.62-0.97), radiculopathy (IRR= 0.59, 91% CI 0.41-0.84), and aseptic arthritis (IRR = 0.81, 95% CI 0.70-0.93) was significantly lower in mRNA-based vaccinees compared to ChAdOx1 vaccinees.
Conclusions: A remarkable platform-dependent difference was observed in the safety profiles of COVID-19 vaccines, particularly for myocarditis/pericarditis and Guillain-Barré syndrome. Nevertheless, the overall risk of AESIs was low for both vaccine platforms.
논문정보
- Research article
- 2023년 12월 (BRIC 등록일 2023-12-18)
- 국내 연구진
- 의약학 > 응용의학
댓글 작성 로그인
팝업 닫기관련 링크
관련분야 연구자보기
관련분야 논문보기
